Radius Health Announces Fourth Quarter and Full-Year 2019 Operating Results

NEXT STORY
Ultragenyx and Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)
PREV STORY
MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novartis data underpin long-term efficacy of Aimovig® where other treatments have failed

author_avatar
NASDAQ Market News

Canada’s nurses celebrate National Nurse Practitioner Week by launching a project to expand NP care to meet growing need

OTTAWA, Nov. 13, 2017 (GLOBE NEWSWIRE) -- In celebration of National Nurse Practitioner (NP) ...

author_avatar
NASDAQ Market News

Neon Therapeutics Named a Top Place to Work in Massachusetts by The Boston Globe

CAMBRIDGE, Mass., Nov. 16, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics (Nasdaq: NTGN) has been ...

author_avatar
NASDAQ Market News